Kowa Gains FDA Breakthrough Status for K-808 in PBC
NAGOYA, Japan, June 30, 2026 Kowa Company, Ltd. has achieved a significant regulatory milestone after the U.S. Food and...
PBC
Advertisement
Gilead’s Livdelzi Achieves Key Phase 3 PBC Trial Goal
FOSTER CITY, California, USA, June 2, 2026 Gilead Sciences has announced positive topline results from the Phase 3 IDEAL...
FDA Grants Priority Review to Zydus Therapeutics’ Saroglitazar for Rare Liver Disease
PENNINGTON, New Jersey and AHMEDABAD, India, May 28, 2026 Zydus Therapeutics, a wholly owned subsidiary of Zydus Lifesciences, has...
Gilead Reports Strong Long-Term Livdelzi PBC Data
FOSTER CITY, Calif., May 28, 2026 Gilead Sciences announced new interim findings from the ongoing Phase 3 ASSURE study...
Assembly Bio Expands ABI-6250 Into Liver Diseases
SOUTH SAN FRANCISCO, Calif., May 22, 2026 Assembly Biosciences announced plans to expand the clinical development of ABI-6250, its...
Advertisement
